BETA-HYDROXYDE™

ACSD
OILY SKIN BALANCER

INTERNAL
BETA-HYDROXYDE™ACSD

 Oily skin treatment

> Claims, positioning and active ingredient

 Beta-Hydroxyde™ ACSD
> Technology
> Efficacy | n e w t e s t i n g s
> Formulation
> Communication
> Strengths
BETA-HYDROXYDE™ACSD

Oily skin treatment

> Claims, positioning
and active ingredients
BETA-HYDROXYDE™ACSD
Claims, positioning, active ingredients

Shine, pore size

> Purity, matt look
> Wide worldwide market
(all ages also includes anti-aging)
> Special focus on asian markets

Exfoliation
> The star is salicylic acid
> Face cleansers
> Oily skin correctors
> Imperfections removal
BETA-HYDROXYDE™ACSD
Claims, positioning, active ingredients

Imperfections, inflammations
> Global action on all concerns
of oily skin
> From shine, black heads, spots,

Sebum regulation, pore cleansing

> Salicylic acid
> Bactericides
> Zinc derivatives
> 4 α-reductase regulators
> Anti-inflammatories
BETA-HYDROXYDE™ACSD

Beta-Hydroxyde™ ACSD
> The technology
> Efficacy
> Formulation
BETA-HYDROXYDE™ACSD
The technology

Beta-Hydroxyde™ challenge

Enhancing salicylic acid properties

while reducing irritating side effects
 BETA-HYDROXYDE™ACSD
The technology

Molecular association

> Salicylic acid coupled with acacia polysaccharides

R A T I O: 50 salicylic acid | 50 acacia protein

acacia polysaccharides

salicylic acid salicylic acid

 BETA-HYDROXYDE™ACSD
The technology

Molecular association

> A I M: reduce salicylic penetration in the deep skin layers

BETA-HYDROXYDE™ACSD

Beta-Hydroxyde™ ACSD
> Efficacy
- In vitro testings
- In vivo testings | n e w
BETA-HYDROXYDE™ACSD
Efficacy

Target the cutaneous surface Ex vivo study on Franz cells

• Comparative transcutaneous
penetration test of
Beta-Hydroxyde™ ACSD
versus free salicylic acid equivalent
(1%) and placebo, at pH 5,
• Measurement by
spectrophotometry.

Diffusion Release Sorage Total

(24h) (48h) (after 72h)

Slows down the penetration speed: -42%

BETA-HYDROXYDE™ACSD
Efficacy

Exfoliating activity In vivo study

Evaluation of the discoloration speed of a
pretreated zone with DiHydroxyAcetone (DHA).
• Study carried out on the forearm of 15
volunteers,
• Application of a 2% Beta-Hydroxyde™
salicylic emulsion, versus free salicylic acid
equivalent (1%) and placebo,
• A 15-day treatment,
• Measurement of the discoloration with a
chromameter.

As efficient as salicylic acid

 BETA-HYDROXYDE™ACSD
Efficacy

Safety

> Not irritant for skin and eye at 10%

> Non sensitizing
> Non mutagenic
BETA-HYDROXYDE™ACSD
Efficacy

New testings
In vivo study
- On 100 volunteers with oily skin and enlarged pores.
- 4 groups of 25 subjects using the product twice a day for 28 days:
> 1 placebo formula,
> 1 formula containing 0.4% of Beta-Hydroxyde™ ACSD (0.2% of salicylic acid),
> 1 formula containing 3% of Beta-Hydroxyde™ ACSD (1.5% of salicylic acid),
> 1 formula containing 1.5% of free salicylic acid (positive control).
- Evaluation are made at D0, D14 et D28.
- Pore size is measured through imprints and laser video microscope analysis.
- Evaluation of clinical aspect by a clinician, scorage according to an analogic scale.
-Auto-evaluation by panelists. Percentage of “yes”.
-Evaluation of shine reduction
 BETA-HYDROXYDE™ACSD
Efficacy

Refines pore size

In vivo study
Imprints and laser video
microscope analysis.
> Pore size reduction at D14

Up to -47.5%
at D28
BETA-HYDROXYDE™ACSD
Efficacy

Number of pores In vivo study

Imprints and laser video
microscope analysis.
> Reduction of number of pores at D14

Up to -13.5%
at D28
BETA-HYDROXYDE™ACSD
Efficacy

Pore volume and number D0-D28 In vivo study

Imprints and laser video
microscope analysis.

Before After a 28-day treatment

with Beta-Hydroxyde™ ACSD 3%
 BETA-HYDROXYDE™ACSD
Efficacy

Shine reduction

> Percentage of panelist who > Sebum production diminishing at

present a sebum diminishing at D14 D14 on the whole panel
 BETA-HYDROXYDE™ACSD
Efficacy

General improvement of oily skin In vivo study

Evaluation by a clinician,
through analogical scale.
> Clinician evaluation

Day 14 Day 28

***: Statistically different from T0 (p<0.001)

**: Statistically different from T0 (p<0.01)
*: Statistically different from T0 (p<0.05)
BETA-HYDROXYDE™ACSD
Efficacy

General improvement of oily skin In vivo study

Auto-evaluation by panelists.
Percentage of Yes.
> Auto-evaluation

Day 14 Day 28
BETA-HYDROXYDE™ACSD
Efficacy

General improvement of oily skin

BETA-HYDROXYDE™ACSD
Strengths

Strengths
> A SOPHISTICATED technology
- Molecular association

> EFFICACY: both mechanism of action and in vivo efficacy are demonstrated
- Quick action as compared to competition which is more 56 days
- The action is visible, both by the clinician and the volunteer

> MORE EFFICIENT than salicylic acid

- Boosted and safe
BETA-HYDROXYDE™ACSD

Beta-Hydroxyde™ ACSD
> Presentation
> Formulation
BETA-HYDROXYDE™ACSD
Presentation

Commercial product

> A powder or a solution

Powder
100% Beta-Hydroxyde™ ACSD (50/50)
Solution
A 15 to 20% solution, gelified
Preservatives: None
BETA-HYDROXYDE™ACSD
Formulation

All cosmetics formulas

Add in the aqueous phase of the emulsion heated

at 70°C – 80°C and make the emulsion.
All types of stirring
Emulsions and gels (may be cloudy)
Concentration of use: 1 to 5%
BETA-HYDROXYDE™ACSD
Technical Data
“Although all statements and information in this publication are believed to be
accurate and reliable, they are presented gratis and for guidance only, and risks and
liability for results obtained by use of the products or application of the suggestions
described are assumed by the user. THERE ARE NO WARRANTIES OF ANY KIND.
ALL EXPRESS AND IMPLIED WARRANTIES ARE DISCLAIMED. Statements or
suggestions concerning possible use of the products are made without representation
or warranty that any such use is free of patent infringement and are not
recommendations to infringe any patent. The user should not assume that toxicity
data and safety measures are indicated or that other measures may not be required.
The claims and supporting data provided in this publication have not been evaluated
for compliance with any jurisdiction’s regulatory requirements and the results reported
may not be generally true under other conditions or in other matrices. Users must
evaluate what claims and information are appropriate and comply with a jurisdiction’s
regulatory requirements. Recipient of this publication agrees to (i) indemnify and hold
harmless each entity of the BASF organization for any and all regulatory action arising
from recipient’s use of any claims or information in this publication, including, but not
limited to, use in advertising and finished product label claims, and (ii) not present this
publication as evidence of finished product claim substantiation to any regulatory
authority."